nach oben

Erschienen in:

01.11.2021 | Neurologie

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

verfasst von: Prim. Univ. Prof. Dr. Johann Sellner, MBA FAAN FANA FEAN

Erschienen in: psychopraxis. neuropraxis | Ausgabe 6/2021

Einloggen, um Zugang zu erhalten

Zusammenfassung

Der Prävention von Infektionskrankheiten kommt bei der Multiplen Sklerose (MS) eine besondere Bedeutung zu, da diese den Krankheitsverlauf ungünstig beeinflussen können. Dies wird uns im Rahmen der COVID-19-Pandemie verdeutlicht, wo die SARS-CoV-2-Infektion als Auslöser von besonders schweren und prolongierten Schüben und klinischer Verschlechterung identifiziert werden konnte. Umso wichtiger ist es daher, den Einfluss der für die MS zugelassenen Immuntherapien auf eine etwaige Suszeptibilität für eine SARS-CoV-2-Infektion, den COVID-19-Krankheitsverlauf und das Impfansprechen zu verstehen. In dieser Übersichtsarbeit werden diese Punkte unter besonderer Berücksichtigung von Cladribin-Tabletten, einer für den hochaktiven MS-Verlauf zugelassenen Immunrekonstitutionstherapie, beleuchtet.

Vorheriger Artikel Schlafstörungen aus psychiatrischer Sicht

Nächster Artikel Update zur Sekundärprophylaxe nach ischämischem Schlaganfall

Morrison EH, Michtich K, Hersh CM (2021) How the COVID-19 pandemic has changed multiple sclerosis clinical practice: results of a nationwide provider survey. Mult Scler Relat Disord 51:102913. https://doi.org/10.1016/j.msard.2021.102913CrossRefPubMedPubMedCentral

Mateen FJ, Rezaei S, Alakel N, Gazdag B, Kumar AR, Vogel A (2020) Impact of COVID-19 on U.S. and Canadian neurologists’ therapeutic approach to multiple sclerosis: a survey of knowledge, attitudes, and practices. J Neurol 267(12):3467–3475. https://doi.org/10.1007/s00415-020-10045-9CrossRefPubMed

Findling O, Sellner J (2021) Second-generation immunotherapeutics in multiple sclerosis: can we discard their precursors? Drug Discov Today 26(2):416–428. https://doi.org/10.1016/j.drudis.2020.11.022CrossRefPubMed

Sellner J, Rommer PS (2021) Multiple sclerosis and SARS-coV‑2 vaccination: considerations for immune-depleting therapies. Vaccines (Basel). https://doi.org/10.3390/vaccines9020099CrossRef

Monschein T, Hartung HP, Zrzavy T, Barnett M, Boxberger N, Berger T, Chataway J, Bar-Or A, Rommer PS, Zettl UK (2021) Vaccination and multiple sclerosis in the era of the COVID-19 pandemic. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2021-326839CrossRefPubMed

Bodini B, Moro E, Jaarsma J, Cunningham E, Sellner J, Walsh D, EANcore COVID-19 Task Force (2021) Lessons learned from patients with neurological diseases at the time of COVID-19: the EFNA-EAN survey. Eur J Neurol. https://doi.org/10.1111/ene.15087CrossRefPubMedPubMedCentral

Akhvlediani T, Jelcic I, Taba P, Pfausler B, Steiner I, Sellner J (2020) What did we learn from the previous coronavirus epidemics and what can we do better: a neuroinfectiological point of view. Eur J Neurol 27(11):e69–e72. https://doi.org/10.1111/ene.14395CrossRefPubMed

Karamyan A, Dunser MW, Wiebe DJ, Pilz G, Wipfler P, Chroust V, Novak HF, Hauer L, Trinka E, Sellner J (2016) Critical illness in patients with multiple sclerosis: a matched case-control study. PLoS ONE 11(5):e155795. https://doi.org/10.1371/journal.pone.0155795CrossRefPubMedPubMedCentral

Marrodan M, Alessandro L, Farez MF, Correale J (2019) The role of infections in multiple sclerosis. Mult Scler 25(7):891–901. https://doi.org/10.1177/1352458518823940CrossRefPubMed

10.

Zabalza A, Cardenas-Robledo S, Tagliani P, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Rodriguez-Barranco M, Rodriguez-Acevedo B, Restrepo V, Luis J, Resina-Salles M, Midaglia L, Vidal-Jordana A, Rio J, Galan I, Castillo J, Cobo-Calvo A, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X (2020) COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response. Eur J Neurol. https://doi.org/10.1111/ene.14690CrossRef

11.

Chaudhry F, Jageka C, Levy PD, Cerghet M, Lisak RP (2021) Review of the COVID-19 risk in multiple sclerosis. J Cell Immunol 3(2):68–77. https://doi.org/10.33696/immunology.3.080CrossRefPubMedPubMedCentral

12.

Mantero V, Abate L, Balgera R, Basilico P, Salmaggi A, Cordano C (2020) Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients. Mult Scler Relat Disord 46:102453. https://doi.org/10.1016/j.msard.2020.102453CrossRefPubMedPubMedCentral

13.

Barzegar M, Mirmosayyeb O, Gajarzadeh M, Afshari-Safavi A, Nehzat N, Vaheb S, Shaygannejad V, Maghzi AH (2021) COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm. https://doi.org/10.1212/NXI.0000000000001001CrossRefPubMedPubMedCentral

14.

Cabreira V, Abreu P, Soares-Dos-Reis R, Guimaraes J, Sa MJ (2021) Multiple sclerosis, disease-modifying therapies and COVID-19: a systematic review on immune response and vaccination recommendations. Vaccines (Basel). https://doi.org/10.3390/vaccines9070773CrossRef

15.

Garjani A, Middleton RM, Hunter R, Tuite-Dalton KA, Coles A, Dobson R, Duddy M, Hughes S, Pearson OR, Rog D, Tallantyre EC, das Nair R, Nicholas R, Evangelou N (2021) COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies. Mult Scler Relat Disord 52:102939. https://doi.org/10.1016/j.msard.2021.102939CrossRefPubMed

16.

Sellner J, Jenkins T, von Oertzen TJ, Bassetti CL, Beghi E, Bereczki D, Bodini B, Cavallieri F, Di Liberto G, Helbok R, Macerollo A, Maia LF, Oreja-Guevara C, Ozturk S, Rakusa M, Sauerbier A, Soffietti R, Taba P, Pisani A, Priori A, Zedde M, Crean M, Burlica A, Twardzik A, Moro E, EANcore COVID-19 Task Force (2021) Primary prevention of COVID-19: Advocacy for vaccination from a neurological perspective. Eur J Neurol. https://doi.org/10.1111/ene.14713CrossRefPubMedPubMedCentral

17.

Achiron A, Dolev M, Menascu S, Zohar DN, Dreyer-Alster S, Miron S, Shirbint E, Magalashvili D, Flechter S, Givon U, Guber D, Stern Y, Polliack M, Falb R, Gurevich M (2021) COVID-19 vaccination in patients with multiple sclerosis: what we have learnt by february 2021. Mult Scler 27(6):864–870. https://doi.org/10.1177/13524585211003476CrossRefPubMedPubMedCentral

18.

Maniscalco GT, Manzo V, Di Battista ME, Salvatore S, Moreggia O, Scavone C, Capuano A (2021) Severe multiple sclerosis relapse after COVID-19 vaccination: a case report. Front Neurol 12:721502. https://doi.org/10.3389/fneur.2021.721502CrossRefPubMedPubMedCentral

19.

Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, Soelberg Sorensen P, Vermersch P, Chang P, Hamlett A, Musch B, Greenberg SJ, CLARITY Study Group (2010) A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 362(5):416–426. https://doi.org/10.1056/NEJMoa0902533CrossRefPubMed

20.

Leist TP, Weissert R (2011) Cladribine: mode of action and implications for treatment of multiple sclerosis. Clin Neuropharmacol 34(1):28–35. https://doi.org/10.1097/WNF.0b013e318204cd90CrossRefPubMed

21.

Rommer PS, Milo R, Han MH, Satyanarayan S, Sellner J, Hauer L, Illes Z, Warnke C, Laurent S, Weber MS, Zhang Y, Stuve O (2019) Immunological aspects of approved MS therapeutics. Front Immunol 10:1564. https://doi.org/10.3389/fimmu.2019.01564CrossRefPubMedPubMedCentral

22.

Comi G, Cook S, Giovannoni G, Rieckmann P, Sorensen PS, Vermersch P, Galazka A, Nolting A, Hicking C, Dangond F (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 29:168–174. https://doi.org/10.1016/j.msard.2019.01.038CrossRefPubMed

23.

Oh J, Walker B, Giovannoni G, Jack D, Dangond F, Nolting A, Aldridge J, Lebson LA, Leist TP (2021) Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis. Mult Scler J Exp Transl Clin 7(3):20552173211024298. https://doi.org/10.1177/20552173211024298CrossRefPubMedPubMedCentral

24.

Dersch R, Wehrum T, Fahndrich S, Engelhardt M, Rauer S, Berger B (2020) COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult Scler 26(10):1264–1266. https://doi.org/10.1177/1352458520943783CrossRefPubMed

25.

Dalla Costa, Leocani L, Montalban X, Guerrero AI, Sorensen PS, Magyari M, Dobson RJB, Cummins N, Narayan VA, Hotopf M, Comi G, RADAR-CNS consortium (2020) Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci 41(7):1647–1650. https://doi.org/10.1007/s10072-020-04519-xCrossRefPubMedPubMedCentral

26.

Czarnowska A, Brola W, Zajkowska O, Rusek S, Adamczyk-Sowa M, Kubicka-Baczyk K, Kalinowska-Lyszczarz A, Kania K, Slowik A, Wnuk M, Marona M, Podlecka-Pietowska A, Nojszewska M, Zakrzewska-Pniewska B, Jasinska E, Goluch K, Lech B, Noga M, Perenc A, Popiel M, Lasek-Bal A, Puz P, Maciejowska K, Kucharska-Lipowska M, Lipowski M, Kapica-Topczewska K, Chorazy M, Tarasiuk J, Kochanowicz J, Kulikowska J, Wawrzyniak S, Niezgodzinska-Maciejek A, Pokryszko-Dragan A, Gruszka E, Budrewicz S, Bialek M, Kurkowska-Jastrzebska I, Kurowska K, Stepien A, Wlodek A, Ptasznik V, Pawelczyk M, Sobolewski P, Lejmel H, Strzalinska K, Maciejowski M, Tutaj A, Zwiernik J, Litwin A, Lewanczyk B, Paprocka I, Zwiernik B, Pawlos A, Borysowicz A, Naroznik A, Michalowska A, Nosek K, Fudala M, Milewska-Jedrzejczak M, Kulakowska A, Bartosik-Psujek H (2021) Clinical course and outcome of SARS-CoV‑2 infection in multiple sclerosis patients treated with disease-modifying therapies—the Polish experience. Neurol Neurochir Pol 55(2):212–222. https://doi.org/10.5603/PJNNS.a2021.0031CrossRefPubMed

27.

Bsteh G, Assar H, Hegen H, Heschl B, Leutmezer F, Di Pauli F, Gradl C, Traxler G, Zulehner G, Rommer P, Wipfler P, Guger M, Enzinger C, Berger T, AUT-MuSC investigators (2021) COVID-19 severity and mortality in multiple sclerosis are not associated with immunotherapy: insights from a nation-wide Austrian registry. PLoS ONE 16(7):e255316. https://doi.org/10.1371/journal.pone.0255316CrossRefPubMedPubMedCentral

28.

Jack D, Damian D, Nolting A, Galazka A (2021) COVID-19 in patients with multiple sclerosis treated with cladribine tablets: an update. Mult Scler Relat Disord 51:102929. https://doi.org/10.1016/j.msard.2021.102929CrossRefPubMedPubMedCentral

29.

De Angelis M, Petracca M, Lanzillo R, Brescia Morra V, Moccia M (2020) Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice. Mult Scler Relat Disord 45:102452. https://doi.org/10.1016/j.msard.2020.102452CrossRefPubMedPubMedCentral

30.

Haham N, Vaknin-Dembinsky A (2021) COVID-19 in Cladribine-treated patient with multiple sclerosis. J Neuroimmunol 359:577690. https://doi.org/10.1016/j.jneuroim.2021.577690CrossRefPubMedPubMedCentral

31.

Celius EG (2020) Normal antibody response after COVID-19 during treatment with cladribine. Mult Scler Relat Disord 46:102476. https://doi.org/10.1016/j.msard.2020.102476CrossRefPubMedPubMedCentral

32.

Seferoglu M, Ethemoglu O, Turan OF, Siva A (2021) MS and COVID-19 challenge: asymptomatic COVID-19 infection during treatment with cladribine. Neurol Sci 42(9):3533–3535. https://doi.org/10.1007/s10072-021-05409-6CrossRefPubMedPubMedCentral

33.

Gelibter S, Orrico M, Filippi M, Moiola L (2021) COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program? Mult Scler Relat Disord 49:102775. https://doi.org/10.1016/j.msard.2021.102775CrossRefPubMedPubMedCentral

34.

Drulovic J, Ivanovic J, Martinovic V, Tamas O, Veselinovic N, Cujic D, Gnjatovic M, Mesaros S, Pekmezovic T (2021) Humoral response to SARS-coV‑2 and COVID-19 vaccines in patients with multiple sclerosis treated with immune reconstitution therapies. Mult Scler Relat Disord 54:103150. https://doi.org/10.1016/j.msard.2021.103150CrossRefPubMedPubMedCentral

35.

Allen-Philbey K, Stennett A, Begum T, Johnson AC, Dobson R, Giovannoni G, Gnanapavan S, Marta M, Smets I, Turner BP, Baker D, Mathews J, Schmierer K (2021) Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. Mult Scler Relat Disord 52:103028. https://doi.org/10.1016/j.msard.2021.103028CrossRefPubMedPubMedCentral

36.

Moser T, Schwenker K, Seiberl M, Feige J, Akgun K, Haschke-Becher E, Ziemssen T, Sellner J (2020) Long-term peripheral immune cell profiling reveals further targets of oral cladribine in MS. Ann Clin Transl Neurol 7(11):2199–2212. https://doi.org/10.1002/acn3.51206CrossRefPubMedPubMedCentral

37.

Gold R, Fätkenheuer G, Hartung HP, Kleinschnitz C, Marks R, Maschke M, Bayas A, Löbermann M, Zettl UK, Wiendl H (2021) Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets. Ther Adv Neurol Disord. https://doi.org/10.1177/17562864211019598CrossRefPubMedPubMedCentral

38.

MS Society UK (Hrsg) (2021) MS society medical advisers consensus statement on MS treatments and COVID-19 vaccines. https://www.mssocietyorguk/what-we-do/news/mssociety-medical-advisers-release-consensus-statement-covid-19-vaccines. Zugegriffen: 23. Mai 2021

39.

National Multiple Sclerosis Society (Hrsg) (2021) https://www.nationalmssociety.org/coronavirus-covid-19-information/multiplesclerosis-and-coronavirus/covid-19-vaccine-guidance/Timing-MS-Medications-withCOVID-19-Vaccines. Zugegriffen: 14. Mai 2021

40.

Rieckmann P, Centonze D, Giovannoni G, Hua LH, Oreja-Guevara C, Selchen D, Sørensen PS, Vermersch P, Wiendl H, Salloukh H, Yamout B (2021) Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice (medRxiv)CrossRef

41.

Buttari F, Bruno A, Dolcetti E, Azzolini F, Bellantonio P, Centonze D, Fantozzi R (2021) COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab. Mult Scler Relat Disord 52:102983. https://doi.org/10.1016/j.msard.2021.102983CrossRefPubMedPubMedCentral

42.

Achiron A, Mandel M, Dreyer-Alster S, Harari G, Magalashvili D, Sonis P, Dolev M, Menascu S, Flechter S, Falb R, Gurevich M (2021) Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies. Ther Adv Neurol Disord 14:17562864211012835. https://doi.org/10.1177/17562864211012835CrossRefPubMedPubMedCentral

43.

Sormani MP, Inglese M, Schiavetti I, Carmisciano L, Laroni A, Lapucci C (2021) Effect of SARS-coV‑2 mRNA vaccination in MS patients treated with disease modifying therapies. EBioMedicine. https://doi.org/10.1016/j.ebiom.2021.103581CrossRefPubMedPubMedCentral

44.

Tallantyre EC, Vickaryous N, Anderson V, Nazli Asardag A, Baker D, Bestwick J, Bramhall K (2021) COVID-19 vaccine response in people with multiple sclerosis (medRxiv)

45.

Gadani SP, Reyes-Mantilla M, Jank L, Harris S, Douglas M, Smith MD, Calabresi PA, Mowry EM, Fitzgerald KC, Bhargava P (2021) Discordant humoral and T cell immune responses to SARS-CoV‑2 vaccination in people with multiple sclerosis on anti-CD20 therapy https://doi.org/10.1101/2021.08.23.21262472 (medRxiv)CrossRef

46.

Hogelin KA, Ruffin N, Pin E, Manberg A, Hober S, Gafvelin G, Gronlund H, Nilsson P, Khademi M, Olsson T, Piehl F, Al Nimer F (2021) Development of humoral and cellular immunological memory against SARS-CoV‑2 despite B‑cell depleting treatment in multiple sclerosis. iScience. https://doi.org/10.1016/j.isci.2021.103078CrossRef

47.

Iannetta M, Landi D, Cola G, Malagnino V, Teti E, Fraboni D, Buccisano F, Grelli S, Coppola L, Campogiani L, Andreoni M, Marfia GA, Sarmati L (2021) T‑cell responses to SARS-CoV‑2 in multiple sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-spike antibody titers. Mult Scler Relat Disord 55:103157. https://doi.org/10.1016/j.msard.2021.103157CrossRefPubMedPubMedCentral

Titel: Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie
verfasst von: Prim. Univ. Prof. Dr. Johann Sellner, MBA FAAN FANA FEAN
Publikationsdatum: 01.11.2021
Verlag: Springer Vienna
Erschienen in: psychopraxis. neuropraxis / Ausgabe 6/2021
Print ISSN: 2197-9707
Elektronische ISSN: 2197-9715
DOI: https://doi.org/10.1007/s00739-021-00761-w

„… da kann sie nichts Positives schildern …“ – Zur Auswirkung des Destruktiven auf die Mentalisierungsfähigkeit

Open Access
Psychiatrie

Schlafstörungen aus psychiatrischer Sicht

Psychiatrie

PRELAPSE-Studie zeigt: Reden hilft!

aktuell

Können Timolol-Augentropfen als Migräneakuttherapie verwendet werden?

Neurologie

Indikator für das Ansprechen auf die Migräneprophylaxe

aktuell

panorama

panorama

Springer Medizin Österreich

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

Zusammenfassung

Weitere Artikel der Ausgabe 6/2021

„… da kann sie nichts Positives schildern …“ – Zur Auswirkung des Destruktiven auf die Mentalisierungsfähigkeit

Schlafstörungen aus psychiatrischer Sicht

PRELAPSE-Studie zeigt: Reden hilft!

Können Timolol-Augentropfen als Migräneakuttherapie verwendet werden?

Indikator für das Ansprechen auf die Migräneprophylaxe

panorama

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

„… da kann sie nichts Positives schildern …“ – Zur Auswirkung des Destruktiven auf die Mentalisierungsfähigkeit

Schlafstörungen aus psychiatrischer Sicht

PRELAPSE-​Studie zeigt: Reden hilft!

Können Timolol-Augentropfen als Migräneakuttherapie verwendet werden?

Indikator für das Ansprechen auf die Migräneprophylaxe

panorama

PRELAPSE-Studie zeigt: Reden hilft!

Indikator für das Ansprechen auf die Migräneprophylaxe